Various aspects of this patent document relate to compositions and methods to purify cannabinoids by crystallization in a water-miscible liquid.

Various aspects of this patent document relate to compositions and methods to purify cannabinoids by crystallization in a water-miscible liquid.

The present disclosure relates to new cannabinoid derivatives and precursors and processes for their preparation. The disclosure also relates to pharmaceutical and analytical uses of the new cannabinoid derivatives.

The present disclosure relates to new cannabinoid derivatives and precursors and processes for their preparation. The disclosure also relates to pharmaceutical and analytical uses of the new cannabinoid derivatives.

Novel compounds, in particular novel peroxisome proliferator-activated receptor (PPAR) agonist compounds, are provided. Pharmaceutical formulations for treating PPAR mediated disorder or condition are also provided. The formulations may be a combination of cannabinoids and the PPAR agonist compounds. The PPAR mediated disorder or condition may include inflammation related diseases such as psoriasis, psoriatic arthritis and atopic dermatitis.

Cannabis plant material is extracted with a solvent matrix consisting of one or more organic solvents and optionally water. The cannabis plant material is agitated in the solvent matrix and then removed by filtration or centrifugation. Following extraction, the plant material is separated from the solvent matrix by centrifugation. The resulting extract is clarified by membrane filtration which also removes most of the water and water-soluble impurities. The resulting extract is dewaxed using membrane filtration and/or liquid-liquid extraction. Excess solvent and terpenoids are removed by means of molecular weight cutoff membrane filtration and the resulting cannabinoid solution is decarboxylated catalytically. Seed crystals are added to crystallize the cannabinoids.

Cannabis plant material is extracted with a solvent matrix consisting of one or more organic solvents and optionally water. The cannabis plant material is agitated in the solvent matrix and then removed by filtration or centrifugation. Following extraction, the plant material is separated from the solvent matrix by centrifugation. The resulting extract is clarified by membrane filtration which also removes most of the water and water-soluble impurities. The resulting extract is dewaxed using membrane filtration and/or liquid-liquid extraction. Excess solvent and terpenoids are removed by means of molecular weight cutoff membrane filtration and the resulting cannabinoid solution is decarboxylated catalytically. Seed crystals are added to crystallize the cannabinoids.

The present invention describes a process for the production of (−)-cannabidiol (CBD) from industrial hemp by means of an extraction followed by two alternative working processes: a process A which provides extraction with solvents first to an alkaline pH and then to acidic pH to isolate the carboxyl form of the CBD which is then subjected to decarboxylation and a process B which provides the elimination of waxes and pitches and then purification by chromatography. At the end of both alternative working processes the CBD is crystallized obtained in high purity crystalline form.

The present invention describes a process for the production of (−)-cannabidiol (CBD) from industrial hemp by means of an extraction followed by two alternative working processes: a process A which provides extraction with solvents first to an alkaline pH and then to acidic pH to isolate the carboxyl form of the CBD which is then subjected to decarboxylation and a process B which provides the elimination of waxes and pitches and then purification by chromatography. At the end of both alternative working processes the CBD is crystallized obtained in high purity crystalline form.

Cannabidiol derivatives and medical use thereof, in particular to the compounds represented by general formula (I), or stereoisomers, solvates, metabolites, prodrugs, pharmaceutically acceptable salts or cocrystals thereof, wherein the definitions of substituents in general formula (I) are the same as those in the description

##STR00001##